New data clarify apomorphine vs ropinirole for canine emesis

CURRENT BRIEF VERSION: A new 2025 study is sharpening the clinical conversation around two common emetic options for dogs: extra-label apomorphine and FDA-approved ropinirole ophthalmic solution. In a blinded randomized crossover trial in 24 healthy dogs, investigators found both drugs were highly effective at inducing emesis, with success rates of 95.8% for IV apomorphine and 100% for ophthalmic ropinirole. The tradeoff was speed and tolerability: apomorphine worked faster, with a median time to first emesis of about 1.5 minutes, while ropinirole took about 7.5 minutes and was associated with more vomiting episodes, longer vomiting duration, more ocular redness, and more frequent need for early antiemetic administration. Ropinirole remains the only FDA-approved emetic for dogs in the U.S., while apomorphine is still used extra-label and often through compounding. A separate 2025 emergency-setting study in 132 client-owned dogs with suspected toxin or foreign-body ingestion reached a similar bottom line in real-world cases: overall emesis success was comparable between ropinirole eye drops and IV apomorphine, but apomorphine produced vomiting sooner. (fda.gov)

Why it matters: For veterinary teams, the comparison is less about whether either drug works and more about fit for the patient, the toxin, and the workflow. Apomorphine may still be the better choice when minutes matter, especially for rapidly absorbed toxicants, but ropinirole offers an on-label, noninvasive option that can be easier to administer and avoids handling a hazardous compounded injectable. In the ER study, dogs were randomized across two specialty hospitals after suspected or confirmed ingestion of toxins or foreign material, underscoring how often this decision comes up in practice. Clinics also need to weigh ropinirole’s slower onset and greater likelihood of prolonged vomiting against its regulatory convenience and ophthalmic route. (vetmed.illinois.edu)

What to watch: Expect more discussion around protocol selection in ER and GP settings as newer comparative data from both healthy-dog and emergency-setting studies continue to define when speed, labeling status, and adverse-effect profile matter most. It is also worth keeping product categories straight: newly approved Emeprev (maropitant citrate injectable) is an antiemetic for treating or preventing vomiting in dogs and cats—not an emetic for decontamination—and its practical selling points include reduced injection pain in dogs, no refrigeration, and expected distributor availability in early 2026. (pubmed.ncbi.nlm.nih.gov)